NCT06048250View on ClinicalTrials.gov

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

March 21, 2026

Study Completion Date

March 21, 2026

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Mezigdomide

Receive PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER